Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will announce its second quarter financial results on August 3, 2021, before U.S. market opening. Following the earnings release, a live conference call will occur at 8:30 a.m. ET. Participants can join the call by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international), using passcode 9991311. A replay will be available for one week post-call. Pacira is known for its commitment to non-opioid pain management, with flagship product EXPAREL® launched in 2012, and acquisition of iovera°® system in 2019.
Pacira BioSciences (Nasdaq: PCRX) announced preliminary unaudited net revenue of $135.6 million for Q2 2021, primarily driven by EXPAREL sales of $130.1 million. Average daily sales of EXPAREL surged to 178% of last year for Q2 and to 120% for June. Despite ongoing challenges due to the COVID-19 pandemic impacting elective surgeries, the company remains optimistic about future growth as conditions normalize. The report also highlights increased interest in iovera° and the company's commitment to non-opioid pain management solutions.
Pacira BioSciences, Inc. (Nasdaq: PCRX) has entered a distribution agreement with Eurofarma Laboratories S.A. for the commercialization of EXPAREL® in 19 Latin American countries, including Brazil and Mexico. This partnership aims to enhance Pacira's presence in a rapidly growing market, allowing Eurofarma to leverage its extensive experience in introducing innovative products. Pacira will earn royalties and milestone payments based on Eurofarma's success in this region, reinforcing its commitment to providing non-opioid pain management solutions.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales of EXPAREL and iovera° totaling $41.2 million and $1.0 million, respectively, for May 2021. Sales for EXPAREL showed strong growth, with average daily sales at 162% of May 2020 and 105% of April 2021. This growth is attributed to increased demand in outpatient and non-elective procedures, despite ongoing impacts from the COVID-19 pandemic. The company continues to report monthly sales data to provide clarity on market conditions.
Pacira BioSciences announced topline results from its Phase 3 STRIDE study for EXPAREL, which failed to meet the primary endpoint of pain reduction from 0 to 96 hours compared to bupivacaine HCl. However, significant reductions in pain and opioid consumption were observed from 24 to 96 hours (p0.01) and cumulative pain scores from 12 to 96 hours (p<0.02). Safety results showed no serious adverse events. The company plans to further analyze the data and discuss next steps with the FDA, emphasizing EXPAREL's potential in opioid-sparing pain management.
PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX) will present at the 2021 Jefferies Virtual Healthcare Conference on June 1, 2021, at 9:30 AM ET. The event can be accessed via the company's website, with a replay available for two weeks after the presentation. Pacira is a leader in non-opioid pain management, known for its long-acting local analgesic EXPAREL®, launched in April 2012. The company aims to reduce opioid reliance and enhance patient care through innovative solutions, including the iovera°® cryoanalgesia device acquired in 2019.
Pacira BioSciences has received a Notice of Allowance from the USPTO for a patent regarding its EXPAREL manufacturing process, extending protection until January 22, 2041. This patent is a key component of the company's strategy to maintain market exclusivity for EXPAREL, a non-opioid pain management solution. The company has invested over $100 million in developing a more efficient manufacturing method. Additionally, Pacira is awaiting FDA approval for its new manufacturing process, with a PDUFA date set for August 6, 2021.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 2021 RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 10:20 AM ET. The virtual event will feature live audio accessible via the company’s website. A replay will be available for two weeks post-event.
Pacira is a leader in non-opioid pain management solutions, known for its long-acting local analgesic, EXPAREL®, which was launched in April 2012. In 2019, the company expanded its portfolio by acquiring the iovera°® system, enhancing its commitment to innovative pain management.
Pacira BioSciences reported preliminary unaudited net product sales for April 2021, achieving $43.1 million for EXPAREL and $1.5 million for iovera°. April's average daily sales of EXPAREL reached 449% of April 2020, driven by a recovery in elective surgeries as COVID-19 restrictions eased. CEO Dave Stack highlighted the growing demand for non-opioid pain management solutions. However, the company continues to face challenges due to the pandemic, which impacted elective surgical procedures. Monthly sales updates will be provided until clearer trends emerge.
Pacira BioSciences (PCRX) reported robust Q1 2021 results with total revenues of $119 million, up from $105.7 million in Q1 2020. GAAP net income reached $10.4 million or $0.24 per share, compared to $8.2 million or $0.19 last year. EXPAREL sales surged to $114.7 million, a notable increase from $101.3 million. The company experienced rising operational expenses at $99.6 million. Pacira continues to navigate COVID-19's impact on elective surgeries, with a strong outlook as recovery progresses.